No Data
No Data
Express News | Merck's sales results in the second quarter of Germany are better than expected, and the company has raised its full-year performance guidance.
Catalyst Watch: Tech Blitz With Apple, Amazon, Microsoft, and Meta on Tap for Earnings
Merck & Co's Options: A Look at What the Big Money Is Thinking
Merck's Combination Urinary Cancer Therapy Receives EMA's Committee Nod
Dividend Roundup: Wells Fargo, General Motors, Merck, Delta Air Lines, and More
The European Medicines Agency's Committee For Medicinal Products For Human Use Adopted A Positive Opinion Recommending Approval Of Merck's Keytruda In Combination With Padcev (Enfortumab Vedotin) For The First-line Treatment Of Unresectable Or Metastatic
No Data